Conduct Type C meeting for ADX-2191
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 Nov 2022
- Due
- 30 Jun 2023
- Checked
- 2 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Aldeyra plans to conduct a Type C meeting with the FDA in the first half of 2023 to discuss the completion of clinical development of ADX-2191”
What we found
Evidence strength A What the grades mean
The company moved the planned Type C meeting for ADX-2191 from the first half of 2023 to the second half of 2023 in filings dated after the original deadline.
-
A Aldeyra Therapeutics, Inc. 10-Q filed 2023-08-03
“Type C meeting with FDA to discuss completion of clinical development for proliferative vitreoretinopathy planned in the second half of 2023” ✓ confirmed on the page
Market reaction: the shares moved -5.7% against the S&P 500 over the three sessions around the disclosure (2 Aug 2023 to 7 Aug 2023). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- Conduct
- Deliverable
- ADX-2191 Type C meeting
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-ALDX-003492 · Corrections policy